CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Regeneron's bid to acquire the bankrupt genetic testing firm 23andMe for $256 million has likely come to an end.

A bankruptcy court approved the $305M sale of 23andMe to a nonprofit led by Anne Wojcicki, raising questions about data ...

Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech ... Under the deal, TTAM will acquire 23andMe’s signature “Personal Genome Service” ...

Genetic testing company 23andMe can proceed with a $305 million sale to the company’s co-founder Anne Wojcicki after a U.S.

TTAM Research Institute, a non-profit public benefit company also founded by Wojcicki, won the auction with a $305 million bid for the 23andMe assets, which will not come with any company liabilities ...

The DNA data of millions of people who used 23andMe's services won't be sold to a pharmaceutical company. A bankruptcy judge ...

A court has approved the $305m sale of 23andMe’s assets to a nonprofit led by former 23andMe CEO Anne Wojcicki.

Regeneron Pharmaceuticals (REGN) exits buyout race for 23andMe as Anne Wojcicki's TTAM Research offers a superior $305M bid. Read more here.

A bankruptcy court gave the green light for TTAM Research Institute - a firm launched by 23andMe's co-founder and former CEO ...

States with privacy objections to the sale have until July 7 to reach a stay to appeal the case. TTAM, a nonprofit started by ...